Skip to content
value.today

Pure Bioscience

Formerly Innovative Medical Services

Total raised
$7 M
4 rounds on record
Latest round
$1 M
Dec 2013
First round on record
Oct 2010
Today
Went public
See the company page

Pure Bioscience is listed today as PURE Bioscience, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Pure Bioscience
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2016$1 MPrivate placement after listingUnder $2 million

Pure Bioscience: Private sale, Dec 2016

Investors in this round

7 investors had bought by the notice of Dec 15, 2016: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$122,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dave R. Pfanzelter · Executive Officer, Director
  • Henry R. Lambert · Executive Officer, Director
  • Mark Y. Elliott · Executive Officer
  • David R. Theno, Jr. · Director
  • Gary R. Cohee · Director
  • Tom Y. Lee · Director
  • William R. Otis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Garden State Securities, Inc. (CRD 10083) · Red Bank, New JerseySold in AZ, ID, IL, NJ

Signed by Mark Elliott, Vice President, Finance. Source: SEC Form D, newest notice filed Dec 15, 2016. Read the notice at the SEC.

equity, optionsSEC
Nov 2015$2 MPrivate placement after listing$2 to $10 million

Pure Bioscience: Private sale, Nov 2015

Investors in this round

13 investors had bought by the notice of Dec 7, 2015: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dave R. Pfanzelter · Executive Officer, Director
  • Henry R. Lambert · Executive Officer, Director
  • Mark Y. Elliott · Executive Officer
  • David R. Theno, Jr. · Director
  • Gary R. Cohee · Director
  • Tom Y. Lee · Director
  • William R. Otis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Elliott, Vice President, Finance. Source: SEC Form D, newest notice filed Dec 7, 2015. Read the notice at the SEC.

equity, optionsSEC
Oct 2015$6 MPrivate placement after listing$2 to $10 million

Pure Bioscience: Private sale, Oct 2015

Investors in this round

1 investor had bought by the notice of Oct 30, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Henry R. Lambert · Executive Officer, Director
  • Mark Y. Elliott · Executive Officer
  • Dave R. Pfanzelter · Director
  • David R. Theno, Jr. · Director
  • Gary R. Cohee · Director
  • Tom Y. Lee · Director
  • William R. Otis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Elliott, Vice President, Finance. Source: SEC Form D, newest notice filed Oct 30, 2015. Read the notice at the SEC.

equity, optionsSEC
Aug 2014$10 MPrivate placement after listing$2 to $10 million

Pure Bioscience: Private sale, Aug 2014

Investors in this round

28 investors had bought by the notice of Sep 4, 2014: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Henry R. Lambert · Executive Officer, Director
  • Peter C. Wulff · Executive Officer
  • Dave R. Pfanzelter · Director
  • David R. Theno, Jr. · Director
  • Gary R. Cohee · Director
  • William R. Otis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Wulff, CFO and COO. Source: SEC Form D, newest notice filed Sep 4, 2014. Read the notice at the SEC.

equity, optionsSEC
Jan 2014$1 MPrivate placement after listingUnder $2 million

Pure Bioscience: Private sale, Jan 2014

Investors in this round

15 investors had bought by the notice of Mar 14, 2014: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $5 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dave R. Pfanzelter · Executive Officer, Director
  • Henry R. Lambert · Executive Officer, Director
  • Peter C. Wulff · Executive Officer
  • Craig C. Culver · Director
  • David R. Theno, Jr. · Director
  • Gary R. Cohee · Director
  • William C. Otis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Wulff, CFO and COO. Source: SEC Form D, newest notice filed Mar 14, 2014. Read the notice at the SEC.

equitySEC
Dec 2013$1 MNo. 4Under $2 million

Pure Bioscience: Raise no. 4, Dec 2013

Investors in this round

8 investors had bought by the notice of Dec 19, 2013: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dave R. Pfanzelter · Executive Officer, Director
  • Henry R. Lambert · Executive Officer, Director
  • Peter C. Wulff · Executive Officer
  • Craig C. Culver · Director
  • David R. Theno, Jr. · Director
  • Gary R. Cohee · Director
  • William C. Otis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Wulff, CFO and COO. Source: SEC Form D, newest notice filed Dec 19, 2013. Read the notice at the SEC.

equitySEC
Oct 2013$2 MNo. 3$2 to $10 million

Pure Bioscience: Raise no. 3, Oct 2013

Investors in this round

40 investors had bought by the notice of Dec 17, 2013: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dave R. Pfanzelter · Executive Officer, Director
  • Henry R. Lambert · Executive Officer, Director
  • Peter C. Wulff · Executive Officer
  • Craig C. Culver · Director
  • David R. Theno, Jr. · Director
  • Gary R. Cohee · Director
  • William C. Otis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Wulff, CFO and COO. Source: SEC Form D, newest notice filed Dec 17, 2013. Read the notice at the SEC.

equitySEC
Aug 2013$1 MNo. 2Under $2 million

Pure Bioscience: Raise no. 2, Aug 2013

Investors in this round

22 investors had bought by the notice of Dec 16, 2013: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dave R. Pfanzelter · Executive Officer, Director
  • Henry R. Lambert · Executive Officer, Director
  • Peter C. Wulff · Executive Officer
  • Craig C. Culver · Director
  • David R. Theno, Jr. · Director
  • Gary R. Cohee · Director
  • William C. Otis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Wulff, CFO and COO. Source: SEC Form D, newest notice filed Dec 16, 2013. Read the notice at the SEC.

equitySEC
Oct 2010$2 MNo. 1$2 to $10 million

Pure Bioscience: Raise no. 1, Oct 2010

Investors in this round

11 investors had bought by the notice of Nov 9, 2010: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Andrew L. Buckland · Executive Officer
  • Donna L. Singer · Executive Officer, Director
  • Michael L. Krall · Executive Officer, Director
  • Dennis L. Brovarone · Director
  • Gregory H. Barnhill · Director
  • John J. Carbone, MD · Director
  • Paul V. Maier · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Buckland, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 9, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company PURE Bioscience, Inc., its revenue in fiscal 2026 came from these product and service lines: PURE Hard Surface $2.18 million (94%), SILVERION $130,000 (6%).

    Annual report (SEC XBRL) · Jul 2026

  • Pure Bioscience had revenue between $1 million and $5 million when it filed its newest notice of a funding round (Dec 2016).

    SEC Form D (revenue range) · Dec 2016

  • Revenue range over time, as stated in its notices: revenue of up to $1 million in 2014; revenue of up to $1 million in 2015; revenue between $1 million and $5 million in 2016.

    SEC Form D (revenue range) · Dec 2016

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2016

Products and services#

No products or services of Pure Bioscience are on record.

Investors#

No investor of Pure Bioscience is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 40 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pure Bioscience
NameRoleNamed in
Dave R. PfanzelterExecutive officerDec 2016
Henry R. LambertExecutive officerDec 2016
Mark Y. ElliottExecutive officerDec 2016
Peter C. WulffExecutive officerSep 2014
Andrew L. BucklandExecutive officerNov 2010
Donna L. SingerExecutive officerNov 2010
Michael L. KrallExecutive officerNov 2010
Dave R. PfanzelterDirectorDec 2016
David R. Theno, Jr.DirectorDec 2016
Gary R. CoheeDirectorDec 2016
Henry R. LambertDirectorDec 2016
Tom Y. LeeDirectorDec 2016
William R. OtisDirectorDec 2016
Craig C. CulverDirectorMar 2014
William C. OtisDirectorMar 2014
Dennis L. BrovaroneDirectorNov 2010
Donna L. SingerDirectorNov 2010
Gregory H. BarnhillDirectorNov 2010
John J. Carbone, MDDirectorNov 2010
Michael L. KrallDirectorNov 2010
Paul V. MaierDirectorNov 2010

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.